Rani Therapeutics Holdings, Inc. (RANI) Key Metrics
RANI valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $90.0M
- Enterprise value
- $38.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 18.5
- Price / book
- 2.3 10-yr median 5.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.71
RANI key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRANI valuation Price multiples at each fiscal year-end price.
Price / sales+44.1%
54.7
2025 · hover or tap a bar for each year
20192025
Price / book−86.2%
2.7
2025 · hover or tap a bar for each year
20192025
Free cash flow yield+70.6 pts
−21.1%
2025 · hover or tap a bar for each year
20192025
RANI returns How much profit the business earns on the capital it uses.
Return on equity+234.5 pts
−169.6%
2025 · hover or tap a bar for each year
20192025
Return on assets+1.2 pts
−62.3%
2025 · hover or tap a bar for each year
20192025
Asset turnover+57.7%
0.03
2025 · hover or tap a bar for each year
20192025
RANI per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−31.6%
$0.02
2025 · hover or tap a bar for each year
20192025
Earnings per share
−$0.45
2025 · hover or tap a bar for each year
20192025
Free cash flow per share
−$0.28
2025 · hover or tap a bar for each year
20192025
Book value per share+613.5%
$0.50
2025 · hover or tap a bar for each year
20192025
Shares outstanding+132.3%
66.1M
2025 · hover or tap a bar for each year
20192025
RANI financial health Debt, liquidity and how easily interest is covered.
Debt / equity−99.1%
0.13
2025 · hover or tap a bar for each year
20192025
Net debt−$47.5M
−$45.4M
2025 · hover or tap a bar for each year
20192025
Current ratio+181.5%
4.21
2025 · hover or tap a bar for each year
20192025
Interest coverage
-13.3
2025 · hover or tap a bar for each year
20192025
Debt / assets−90.9%
0.07
2025 · hover or tap a bar for each year
20192025
RANI efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+165 days
276 days
2025 · hover or tap a bar for each year
20192025
Days payables outstanding
338 days
2025 · hover or tap a bar for each year
20192025
Capex / revenue−20.7 pts
5.4%
2025 · hover or tap a bar for each year
20192025
RANI valuation history
Fiscal year-endToday7-year median
RANI returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RANI debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RANI cash returned to shareholders
DividendsBuybacksFree cash flow
RANI price vs earnings per share
Share price at year-endEPS (right axis)
RANI key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $89.3M | $39.0M | $84.7M | $140.5M | — | — | — |
| Enterprise value | $43.9M | $41.1M | $66.2M | $72.3M | — | — | — |
| Price / sales | 54.7 | 37.9 | — | — | — | — | — |
| Price / book | 2.7 | 19.6 | 6.6 | 3.8 | — | — | — |
| EV / sales | 26.9 | 40.0 | — | — | — | — | — |
| Earnings yield | −33.2% | −76.9% | −40.1% | −21.8% | — | — | — |
| Free cash flow yield | −21.1% | −91.7% | −62.0% | −34.3% | — | — | — |
| Dividend yield | — | — | — | 21.1% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | 0.0% | 21.1% | — | — | — |
| Share price at fiscal year-end | $1.35 | $1.37 | $3.32 | $5.90 | $16.35 | — | — |
| Per share | |||||||
| Revenue per share | $0.02 | $0.04 | $0.00 | $0.00 | — | — | — |
| Earnings per share | −$0.45 | −$1.05 | −$1.33 | −$1.28 | — | — | — |
| Operating cash flow per share | −$0.28 | −$1.25 | −$2.01 | −$1.95 | — | — | — |
| Free cash flow per share | −$0.28 | −$1.26 | −$2.06 | −$2.02 | — | — | — |
| Cash per share | $0.75 | $0.97 | $1.90 | $4.13 | — | — | — |
| Book value per share | $0.50 | $0.07 | $0.50 | $1.55 | — | — | — |
| Tangible book value per share | $0.50 | $0.07 | $0.50 | $1.55 | — | — | — |
| Dividends per share | — | — | — | $1.24 | — | — | — |
| Capex per share | $0.00 | $0.01 | $0.05 | $0.07 | — | — | — |
| Debt per share | $0.07 | $1.04 | $1.18 | $1.27 | — | — | — |
| Shares outstanding | 66.1M | 28.5M | 25.5M | 23.8M | — | — | — |
| Change in shares outstanding | +132.3% | +11.6% | +7.1% | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −169.6% | −404.1% | −136.6% | −72.6% | — | — | — |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −916.5% |
| Return on assets (ROA) | −62.3% | −63.5% | −40.9% | −26.3% | −8.2% | −32.6% | −115.5% |
| Return on tangible assets | −50.6% | −81.9% | −58.7% | −28.3% | −6.7% | −21.0% | −115.5% |
| Financial health | |||||||
| Total debt | $4.3M | $29.7M | $30.1M | $30.2M | — | $3.8M | $115.5M |
| Cash & short-term investments | $49.7M | $27.6M | $48.5M | $98.5M | $117.5M | $73.1M | $16.5M |
| Net debt | −$45.4M | $2.1M | −$18.4M | −$68.3M | −$117.5M | −$69.3M | $99.0M |
| Debt / equity | 0.13 | 14.91 | 2.34 | 0.82 | — | — | — |
| Debt / assets | 0.07 | 0.81 | 0.52 | 0.28 | — | 0.05 | 5.02 |
| Current ratio | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 | 14.12 | 4.84 |
| Quick ratio | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 | 14.12 | 4.84 |
| Interest coverage | -13.3 | -10.6 | -13.0 | -59.2 | -110.7 | -133.4 | — |
| Working capital | $40.7M | $9.9M | $42.9M | $96.1M | $117.0M | $69.6M | $13.4M |
| Invested capital | −$12.4M | $4.1M | −$5.6M | −$31.4M | −$70.0M | −$182.6M | $2.3M |
| Tangible asset value | $41.5M | $3.5M | $25.4M | $74.0M | $121.6M | −$113.3M | −$96.6M |
| Net current asset value | $36.2M | −$3.4M | $18.4M | $66.9M | $117.0M | −$117.8M | −$102.7M |
| Graham net-net per share | $0.52 | −$0.18 | $0.64 | $2.71 | — | — | — |
| Capital allocation | |||||||
| Dividends paid | — | — | — | $29.6M | — | — | — |
| Share buybacks (net) | — | $0 | $162 | $626 | — | — | — |
| Capex / revenue | 5.4% | 26.1% | — | — | 18.6% | 259.7% | 161.5% |
| Capex / depreciation | 0.10 | 0.26 | 1.50 | 2.95 | 1.02 | 2.04 | 2.80 |
| Stock-based compensation / revenue | 722.5% | 1,559.4% | — | — | 831.6% | 0.0% | — |
| R&D / revenue | 1,237.3% | 2,595.5% | — | — | 974.7% | 2,606.9% | 2,510.6% |
| SG&A / revenue | 1,208.7% | 2,329.4% | — | — | 1,024.4% | 1,074.0% | 353.9% |
| Efficiency | |||||||
| Days sales outstanding | 276.0 | 111.5 | — | — | — | 778.2 | 93.2 |
| Days payables outstanding | 338.2 | — | 468.0 | 353.3 | — | — | — |
| Cash conversion cycle (days) | -62.2 | — | — | — | — | — | — |
| Receivables turnover | 1.32 | 3.27 | 0.00 | — | — | 0.47 | 3.92 |
| Payables turnover | 1.08 | 0.00 | 0.78 | 1.03 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | 0.00 |
| Asset turnover | 0.03 | 0.02 | 0.00 | 0.00 | 0.03 | 0.01 | 0.04 |
| Average receivables | $1.2M | $314,000 | $200,000 | — | — | $985,000 | $250,000 |
| Average payables | $834,000 | $1.0M | $1.1M | $1.3M | $808,500 | $367,500 | $198,000 |
| Average inventory | — | — | — | — | — | — | $1 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from RANI's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RANI valuation and financial ratios
Rani Therapeutics earned a return on equity of −169.6% in fiscal 2025. It ended the year with $4.3 million of debt and $49.7 million in cash and short-term investments, a net cash position of $45.4 million.
See the RANI income statement, the RANI chart for price history, or the RANI stock overview for the latest quote and news.
RANI key metrics FAQ
What is Rani Therapeutics's return on equity?
Rani Therapeutics's return on equity (ROE) was −169.6% in fiscal 2025: net income of -$29.7 million on average shareholders' equity of $17.5 million.
How much debt does Rani Therapeutics have?
Rani Therapeutics had total debt of $4.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.13 and more cash than debt.
What is Rani Therapeutics's free cash flow yield?
Rani Therapeutics generated -$18.8 million of free cash flow in fiscal 2025, a free cash flow yield of −21.1% on its market value at year-end ($89.3 million).
What is Rani Therapeutics's current ratio?
Rani Therapeutics's current ratio was 4.21 at the end of fiscal 2025: current assets were 4.21 times current liabilities.